A critique of recent studies on placebo effects of antidepressants: importance of research on active placebos

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Psychopharmacology

• Publication date

  2000-07-22

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s002130000509PMID 11041309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Active control equivalence trials: some methodological aspects

  2005cited by this paper
• Methodology of measuring the efficacy of antidepressants

  2005cited by this paper
• Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial

  2004cited by this paper
• Clinical and statistical issues in therapeutic equivalence trials

  2004cited by this paper
• Are drug and placebo effects in depression additive?

  2000cited by this paper
• Placebo-controlled trials: when are they needed?

  1999cited by this paper
• Caffeine-associated stimuli elicit conditioned responses: an experimental model of the placebo effect

  1999cited by this paper
• Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?

  1999cited by this paper
• How should efficacy be evaluated in randomized clinical trials of treatments for depression?

  1999cited by this paper
• Comorbidity of anxiety and unipolar mood disorders.

  1998cited by this paper
• Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication

  1998cited by this paper
• Need for a New Paradigm for the Clinical Trials of Antidepressants

  1998cited by this paper
• Meta-analysis of trials comparing antidepressants with active placebos

  1998influential reference
• Commentary: Meta-analysis of trials comparing antidepressants with active placebos

  1998cited by this paper
• Factors that influence the outcome of placebo-controlled antidepressant clinical trials.

  1997cited by this paper
• [Is the placebo still ethically acceptable and scientifically useful in clinical drug experimentation?].

  1996cited by this paper
• Clinical and Subclinical Hypothyroidism in Patients with Chronic and Treatment-Resistant Depression

  1996cited by this paper
• Antidepressant Treatment of Depression: A Metaanalysis

  1996cited by this paper
• Augmentation strategies: focus on anxiolytics.

  1996cited by this paper
• Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.

  1996cited by this paper
• The role of acetylcholine mechanisms in mood disorders

  1995cited by this paper
• Thyroid Hormone Treatment of Depression

  1995cited by this paper
• Inert Placebo Versus Active Medication: Patient Blindability in Clinical Pharmacological Trials

  1994cited by this paper
• Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.

  1994cited by this paper
• The natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy.

  1994cited by this paper
• A Meta‐Analysis of Fluoxetine Outcome in the Treatment of Depression

  1994cited by this paper
• Lithium

  1993cited by this paper
• A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.

  1993cited by this paper
• Conditioned responses in pharmacotherapy research

  1993cited by this paper
• Further evidence that a placebo response to antidepressants can be identified.

  1993cited by this paper
• Paroxetine versus placebo: a double-blind comparison in depressed patients.

  1992cited by this paper
• Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output.

  1992cited by this paper
• Chronicity of depressive episode in relation to antidepressant-placebo response.

  1991cited by this paper
• Conditioned drug effects

  1990cited by this paper
• National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments.

  1989cited by this paper
• Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression.

  1989cited by this paper
• Fluoxetine, a Selective Serotonin Uptake Inhibitor, for the Treatment of Outpatients with Major Depression

  1988cited by this paper
• Adinazolam mesylate and placebo in depressed outpatients: a 6-week, double-blind comparison.

  1988cited by this paper
• Adinazolam mesylate and placebo in depressed outpatients: a 6-week, double-blind comparison.

  1988cited by this paper
• How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine.

  1986cited by this paper
• A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.

  1985cited by this paper
• Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress

  1984cited by this paper
• Review of placebo-controlled trials with bupropion.

  1983cited by this paper
• Adrenergic-cholinergic balance and the treatment of affective disorders.

  1983cited by this paper
• Placebo control conditions: Tests of theory or of effectiveness?

  1983cited by this paper
• Isocarboxazid. Efficacy and tolerance.

  1983cited by this paper
• Trazodone in depressed outpatients.

  1982cited by this paper
• Treatment of Neurotic Depression with a New Antidepressant

  1981cited by this paper
• Amoxapine and imipramine in the treatment of depressed outpatients: a controlled study.

  1981cited by this paper
• Maprotiline versus imipramine and placebo in neurotic depression.

  1981cited by this paper
• Maprotiline versus imipramine and placebo in neurotic depression.

  1981cited by this paper
• A multiple-dose, controlled study of phenelzine in depression-anxiety states.

  1976cited by this paper
• Parasympathetic suppression of manic symptoms by physostigmine.

  1973cited by this paper
• The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.

  1973cited by this paper
• Controlled Trial of Amitriptyline in General Practice

  1971cited by this paper

• Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders: A Narrative Review.

  2025cites this paper
• Impact of active placebo controls on estimated drug effects in randomised trials: a systematic review of trials with both active placebo and standard placebo.

  2023cites this paper
• Active placebo versus standard placebo control interventions in pharmacological randomised trials

  2019cites this paper
• Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview.

  2017cites this paper
• Neuro-BioBehavioral Mechanisms of Placebo and Nocebo Responses : Implications for Clinical Trials and Clinical Practice

  2015influential citation
• Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice

  2015cites this paper
• Depression treatment by withdrawal of short-term low-dose antipsychotic, a proof-of-concept randomized double-blind study.

  2014cites this paper
• Plasebo Etkili Midir? Etik Midir?

  2009cites this paper
• Invasion of the Body Snatchers: Prescription Privileges, Professional Schools, and the Drive to Create a New Behavioral Health Profession

  2006cites this paper
• Methodological Issues in Clinical Trials of Antidepressant Medications: Perspectives from Psychotherapy Outcome Research

  2004cites this paper
• Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?

  2004cites this paper
• Use of a fibrin preparation in the engineering of a vascular graft model.

  2004cites this paper
• When are medication side effects due to the nocebo phenomenon

  2002cites this paper
• Evidence-based practice in family therapy: adolescent depression as an example.

  2002cites this paper
• When are medication side effects due to the nocebo phenomenon?

  2002cites this paper
• The Use and Usefulness of Placebo Controls

  2001cites this paper